Neurofibromatosis Type 1 and Risk of Skin Cancer
Open Access
- 1 October 2022
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 158 (10) , 1214-1216
Abstract
Neurofibromatosis type 1 (NF1) is a multisystem autosomal dominant genetic syndrome affecting 1 in 4000 individuals and characterized by heterozygous loss of the tumor suppressor gene, neurofibromin.1 Patients with NF1 develop benign skin, eye, and nervous system tumors and susceptibility to nervous system and other solid organ cancers.1,2 Biallelic loss of NF1 (OMIM 613113) leads to hyperactivation of RAS signaling pathways.3 Although patients with NF1 often present to dermatologists for skin concerns, the risk of basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma in these patients remains unclear.Keywords
This publication has 6 references indexed in Scilit:
- Prognostic Significance of RAS Mutations and P53 Expression in Cutaneous Squamous Cell CarcinomasGenes, 2020
- Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell CarcinomaJournal of Investigative Dermatology, 2019
- Prevalence of neurofibromatosis type 1 in the Finnish populationGenetics in Medicine, 2018
- The NF1 gene in tumor syndromes and melanomaLaboratory Investigation, 2017
- Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomasNature Genetics, 2015
- Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage studyBritish Journal of Cancer, 2012